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Summary
Dendritic cells (DCs) initiate adaptive immune re-
sponses by activating T cells via cognate interactions
between MHC-peptide complexes and T cell recep-
tors. In immature DCs, MHC class II is predominantly
stored in late endocytic compartments, where it has
a short half-life because of degradation. In contrast,
mature DCs recruit MHC class II to the plasma mem-
brane. We here demonstrate that in immature DCs,
the b-chain of MHC class II was oligoubiquiti-
nated after proteolytic processing of the associated
invariant chain in endosomes and that this modifi-
cation was required for efficient endocytosis and sort-
ing into luminal vesicles of multivesicular bodies.
Ubiquitination of MHC class II was suppressed in lipo-
polysaccharide-activated DCs. Mutated MHC class II
lacking its ubiquitination site was expressed at the
plasma membrane, irrespective of DC maturation.
Together, these data provide a molecular basis for
the regulation of MHC class II-mediated antigen pre-
sentation by DCs.
*Correspondence: w.stoorvogel@vet.uu.nlIntroduction
Dendritic cells (DCs) are crucial initiators of adaptive im-
mune responses (Banchereau et al., 2000). Toward this
task, they take up pathogens from peripheral tissues
by endocytic mechanisms, and internalized proteins
are proteolytically processed into peptides that can be
loaded onto major histocompatibility complex (MHC)
molecules. Pathogen products and other ‘‘danger’’ sig-
nals induce a DC maturation program that includes
effective loading of MHC class II (MHC II) with patho-
gen-derived peptides in endosomes and transport of
the MHC II-peptide complexes to the plasma mem-
brane. At the same time, maturing DCs migrate from
peripheral tissues to secondary lymphoid organs where
they can present surface-exposed MHC II-peptide
complexes to CD4+ T cells.
Multivesicular bodies (MVB) are specialized endoso-
mal compartments that are composed of a single limit-
ing membrane (LM) surrounding multiple luminal vesi-
cles. The luminal vesicles (LV) are formed from the LM
by budding inwards, away from the cytosol, and accu-
mulate MHC II in immature DCs (Kleijmeer et al., 2001).
MVB fuse with lysosomes, and this pathway is crucial
for the downregulation and degradation of many mem-
brane proteins and thus may also explain the abundant
presence of MHC II in lysosomes (Barois et al., 2002) and
its relative short half-life in immature DCs (Villadangos
et al., 2005). Alternatively, the MVB may fuse with the
plasma membrane, releasing their LV, now termed exo-
somes (Thery et al., 2002). DC-derived exosomes have
been shown to have immuno-modulatory characteris-
tics, both in vitro and vivo (Thery et al., 2002).
In mature DCs, downregulation of newly synthesized
MHC II via the MVB-lysosomal degradation pathway is
likely to be inhibited, thereby increasing expression of
MHC II at the cell surface. Although crucial, the molecu-
lar mechanism(s) of regulation for MHC II traffic within
the endocytic tract of DCs has not been resolved (Trom-
betta and Mellman, 2005).
Both endocytosis and sorting of endocytosed proteins
at MVB is often triggered by ubiquitination of their
cytoplasmic domain (Staub and Rotin, 2006). It has re-
cently been proposed that oligoubiquitination allows
high-avidity interactions with endocytic adaptors (Bar-
riere et al., 2006; Hawryluk et al., 2006) that facilitate
clathrin-mediated endocytosis. After uptake, ubiquiti-
nated cargo is sorted at the MVB into LV. This depends
on the hepatocyte growth factor-regulated tyrosine ki-
nase substrate Hrs/Vps27 and three protein complexes
termed ESCRT-I, II, and III (endosomal sorting complex
required for transport) that act sequentially in the sorting
of ubiquitinated proteins at MVB (Babst, 2005).
We here report that in immature DCs, MHC II-b is
oligoubiquitinated after the degradation of associated
invariant chain (Ii) in endosomes. Ubiquitination of
MHC II-b is inhibited in activated DCs, resulting in in-
creased cell-surface expression. These observations
indicate that antigen presentation by DCs is efficiently
regulated through ubiquitination of MHC II-b.
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MHC II-b Is Ubiquitinated in the Endocytic Pathway
To study whether MHC II or MHC II-associated proteins
are ubiquitinated, we used both primary bone marrow-
derived DCs (BMDC) and D1 cells. The latter are long-
term cultured myeloid mouse DCs that have been dem-
onstrated in many aspects to have indistinguishable
behavior from freshly isolated DCs (Winzler et al., 1997)
and have the advantage that they can be cultured in large
quantities without contaminating cell types. MHC II-ab
complexes were immunoprecipitated from cell lysates
with different antibodies. From the eluate, ubiquitinated
proteins were selectively reprecipitated with an antibody
recognizing both mono- and oligoubiquitinated proteins,
P4D1 (Haglund et al., 2003). Subsequent immunoblotting
for MHC II-bor ubiquitin (Figure 1A) revealed a character-
istic ladder of ubiquitinated protein bands, spaced at
w8 kDa between 50 and 70 kDa. The two major bands
at 50 kDa and 58 kDa were also observed in parallel
silver-stained gels (Figure 1B) and analyzed by liquid
chromotography/mass spectrometry/mass spectrome-
try (LC-MS/MS) (data not shown). Both ubiquitin and
Ab-b were detected with a sequence coverage of >40%,
whereas MHC II-a was not detected in these samples.
The positive identification of MHC II-b and ubiquitin at
the same position by immunoblotting (Figure 1A) and
mass spectrometry indicate ubiquitinated MHC II-b. Im-
munoblot analyses for MHC II-b of total immunoprecipi-
tated MHC II (Figure 1C) did not reveal a clear signal at
50–70 kDa, indicating that only a minor fraction of total
MHC II-b is ubiquitinated. Ubiquitinated MHC II-b was
detected both in D1 cells and in BMDC but not in
BMDC from MHC II-b KO mice (Figure 1C). Together,
these results show that MHC II-b is oligoubiquitinated
in mouse DCs.
MHC II-b Is Ubiquitinated after Ii Processing
in the Endocytic Pathway
Degradation of the two full-length Ii splice variants, p31
and p41, is initiated in endosomes at their exoplasmic
domain, resulting in the subsequent formation of inter-
mediate degradation products, p18 and p10. Next,
processing of p10 results in the formation of the contig-
uous internal segment of Ii (CLIP). CLIP remains associ-
ated to the peptide binding groove of MHC II, thereby
preventing binding of other peptides. Replacement of
CLIP on MHC II by antigen-derived peptides is aided
by an accessory molecule, DM, and peptide loading of
MHC II occurs primarily within the endocytic tract. To
narrow down the intracellular location of MHC II-b ubiq-
uitination in relation to processing of associated Ii, MHC
II was immunoprecipitated with either one of three anti-
bodies with distinct specificities: M5/114 recognizes all
MHC II, irrespective of associated Ii, Y3P recognizes
MHC II complexes only after p31 or p41 processing,
and 15G4 recognizes the CLIP domain of Ii (Beers
et al., 2005). We further exploited the characteristic sta-
bility of MHC II complexes in SDS (Sadegh-Nasseri and
Germain, 1991). In the presence of SDS, MHC II-ab
dimers dissociated within 30 min at room temperature
when associated with p31, p41, or CLIP, whereas pro-
longed incubations at 20C and heating to 100C were
required to dissociate p10- and peptide-associatedMHC II, respectively (Figures 2A and 2B). Collectively,
these data suggested that MHC II-b is ubiquitinated
only when associated to peptide-loaded MHC II (Fig-
ure 2B). This was confirmed by 2D gel analysis
(Figure 2C). In the first dimension, ubiquitinated MHC
II-b, which was immunoprecipitated from D1 and eluted
at 20C, migrated as a 75–90 kDa complex. Ubiquiti-
nated MHC II-b dissociated from these complexes at
100C as monitored in the second dimension. The fact
that MHC II was ubiquitinated only after processing of
Ii by lysosomal proteases excludes the possibility that
MHC II-b was ubiquitinated in response to misfolding
at the endoplasmic reticulum, for premature retrieval
and proteasomal degradation. It also excludes the
idea that ubiquitination of MHC II may be related to sort-
ing at the trans-Golgi network. Given that ubiquitinated
MHC II has been loaded with peptide, we anticipated
that Ii processing may be required for ubiquitination of
MHC II-b. To test this directly, we used the cysteine
and serine protease inhibitors leupeptin and E64d to
interfere with the processing of MHC II-associated Ii in
endosomes and lysosomes (Neefjes and Ploegh, 1992;
Neumann et al., 2001). In addition, we tested the effect
of MG132, a proteasome inhibitor that is known to block
ubiquitin-dependent sorting of membrane proteins at
MVB (Longva et al., 2002), but also inhibits lysosomal
proteases (Fuertes et al., 2003). All three reagents inter-
fered with Ii processing, as indicated by the accumula-
tion of the MHC II-associated Ii degradation inter-
mediates, p18 and p10, and reduced MHC II peptide
loading (Figure 3A). All three reagents also reduced the
amount of ubiquitinated MHC II-b. Ubiquitination
amounts correlated with the relative efficiencies of inter-
ference with Ii processing, indicating that Ii processing
in the endocytic pathway is required for subsequent
ubiquitination of MHC II-b.
Ubiquitination of MHC II-b Diminishes during DC
Maturation
To test whether maturing DCs ubiquitinate MHC II-b, D1
were treated with lipopolysaccharide (LPS). Maturation
of DCs was indicated by increased cell-surface expres-
sion of MHC II and costimulatory molecules (data not
shown) and relative increase of SDS-resistant peptide-
MHC II complexes (Figure 3B). According to these crite-
ria, maturation was not yet observed after 2 hr of LPS
treatment but was clearly evident after 24 hr. In contrast,
ubiquitination of MHC II-b was diminished already after
2 hr and partially reappeared from 4 hr onward, whereas
the total of MHC II slightly increased during 24 hr
(Figure 3B). The amount of total ubiquitinated proteins
in cell lysates remained constant up to 4 hr but was
reduced at 24 hr (Figure 3B, left). Together, these obser-
vations indicate that ubiquitination of MHC II is selec-
tively regulated and demonstrate a correlation between
ubiquitination and intracellular retention of MHC II in
immature DCs.
Intracellular Retention of MHC II Requires
Ubiquitination of MHC II-b on Lysine 225
MHC II-b contains a single lysine residue at position 225,
which is highly conserved among MHC II-b haplotypes
and mammalian species. To test whether this resi-
due is targeted by the ubiquitination machinery, we
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887Figure 1. MHC II-b Is Oligoubiquitinated
(A) MHC II was immunoprecipitated from 106
D1 cells with M5/114, Y3P, or an isotype
control antibody for M5/114 (1st IP) as indi-
cated. Immunoprecipitates were eluted from
the beads and reprecipitated with ubiquitin
antibodies (2nd IP). Those precipitates were
analyzed by immunoblotting (WB) for ubiqui-
tin or MHC II-b, with either monoclonal M5/
114, an isotype control monoclonal antibody,
or a polyclonal antibody. The positions of
ubiquitinated MHC II-b, MHC-b, and back-
ground IgG from the first IP as indicated.
The figure is representative for three indepen-
dent experiments.
(B) Ubiquitinated MHC II was immunoprecip-
itated from 109 D1 cells as described above.
A small aliquot (0.1%) was analyzed by immu-
noblotting for ubiquitin as reference (WB),
and the remainder was separated by SDS-
PAGE and silver stained. The bands indicated
in the middle lane were identified by mass
spectrometry (data not shown) and contain
both ubiquitin and MHC II-b. The figure is
representative for two independent experi-
ments.
(C) D1 cells or BMDC from WT or Ab-b KO
mice were lysed and MHC II was immunopre-
cipitated (IP). Immunoprecipitates were
eluted at 100C and immunoblotted (WB) for
MHC II-b or ubiquitin as indicated. The figure
is representative for three independent
experiments.expressed wild-type and mutant Ak-b, in which lysine
225 was replaced by an alanine inD1 cells. Ak-befficiently
forms haplotype-mismatched heterodimeric complexes
with Ab-a, and surface expression of Ak-b–Ab-a dimers is
as efficient as that of endogenous Ab-b–Ab-a dimers
(Layet and Germain, 1991). This was confirmed by the
formation of SDS-stable Ab-a–Ak-b-peptide complexes
(data not shown) and a normal subcellular distribution
of these complexes in transduced D1 cells (see below).
Furthermore, the distribution of Ab-a in Ab-b-deficient
BMDC expressing Ak-b was indistinguishable from Ab-a
in wild-type BMDC (Figure 4A), indicating efficient
rescue of the distribution of MHC class II in these
transduced cells. Expressing Ak-b in D1 cells allowed
us to simultaneously detect two distinct MHC II
complexes in the same cells via Ak-b- and Ab-b-specific
antibodies.
Both transduced wild-type Ak-b and mutant Ak-bK225A
were detected by immunoblotting immunoisolated
Ab-a–Ak-b complexes (Figure 4B). The signal for Ak-
bK225A was much higher compared to that of wild-type
Ak-b, probably as a result of a prolonged half-life of Ak-
bK225A (see below). Transduced wild-type Ak-b but notmutant Ak-bK225A was ubiquitinated, demonstrating
linkage of oligoubiquitin to lysine 225. Transduced
wild-type Ak-b localized together with endogenous
Ab-b to intracellular DM-containing compartments (Fig-
ure 4C), again indicating that the exogenous mixed
haplotype MHC II were properly assembled and tar-
geted from the ER to endocytic compartments.
In contrast to endogenous Ab-b and wild-type Ak-b,
which in immature D1 cells colocalized to the same
endocytic compartments, ubiquitination-deficient Ak-
bK225A was primarily found at the plasma membrane
(Figure 4C). These experiments also showed that the
cells did not mature as a consequence of the transduc-
tion procedure, which was confirmed by the lack of the
activation marker CD86 (data not shown). After LPS
treatment, Ab-b, Ak-bWT, and Ak-bK225A were primarily
present at the plasma membrane along with CD86
(data not shown), indicating that all constructs could
be recruited from intracellular MHC II-containing com-
partments (MIIC) to the plasma membrane during matu-
ration. Premature recruitment of Ak-bK225A to the plasma
membrane was also observed in isolated BMDC from
Ab-b KO mice (Figure 4A). Together, these data indicate
Immunity
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Processing of Associated Ii
(A) MHC II was immunoprecipitated (IP) from
D1 cell lysates as indicated by either M5/114,
Y3P, or 15G4, eluted from the beads in SB at
20C or 100C, and immunoblotted (WB) for
MHC II-b, Ii, or ubiquitin. The figure is repre-
sentative for four independent experiments.
(B) Summary of the results in (A). M5/114 pre-
cipitated all MHC II complexes, irrespective
of Ii processing. Y3P precipitated all MHC II
complexes except those containing full-
length Ii (two splice variants, p41 and p31).
15G4 recognizes the CLIP domain of Ii and
therefore precipitated all MHC II complexes
except mature MHC II-peptide and ubiquiti-
nated MHC II.
(C) MHC II was immunoprecipitated with Y3P,
eluted in SB at 20C, and separated by SDS-
PAGE in a first dimension. The lane was ex-
cised, incubated at 100C in SB, separated
in a second dimension by SDS-PAGE, and
immunoblotted for ubiquitin. Appropriate
immunoblots of in parallel prepared 1D lanes
are projected above and to the right of the 2D
blot. Ubiquitinated MHC II-b dissociated only
after incubation at 100C. The figure is repre-
sentative for two independent experiments.that ubiquitination of MHC II-b occurs at lysine 225 and
is required for intracellular retention of MHC II in imma-
ture DCs.
Ubiquitination of MHC II-bStimulates Targeting to LV
We anticipated that the lack of intracellular retention of
Ak-bK225A could be due to a sorting deficiency at MVB.
To test this directly, we performed immunoelectron
microscopy on ultrathin cryosections of immature
(transduced) D1 (Figure 5). Consistent with earlier obser-
vations (Kleijmeer et al., 2001), in nontransduced D1
most of the endogenous MHC II in MVB was associated
with LV (74%) rather than with the LM (Figures 5Aa and
5B). In cells transduced for Ak-bWT, similar amounts of
Ak-bWT (82%) and endogenous MHC II were associated
with LV (Figures 5Ab and 5B). In contrast, in cells trans-
duced with Ak-bK225A, only little (16%) was found in
association with LV, whereas the distribution of endog-
enous Ab-b was only slightly affected (Figures 5Ac and
5B). Together, these data indicate that ubiquitination
of MHC II-b is required for sorting at MVB. Failure of
ubiquitination would result in transfer by default to the
plasma membrane.
Ubiquitination of MHC II-b Is Required for Efficient
Endocytosis of MHC II
In immature but not in mature DCs, MHC II is efficiently
taken up from the plasma membrane by endocytosis
and targeted to MIIC (Chow et al., 2002; Villadangos
et al., 2001). Lack of intracellular retention of Ak-bK225A
could thus also result from inefficient endocytosis. To
study endocytosis, we took advantage of the possibility
to compare simultaneous uptake of endogenous Ab and
transduced mutant or wild-type Ak-b in single cells with
fluorescence microscopy. Transduced D1 cells were
allowed to internalize labeled monoclonal antibodies
that specifically recognize Ak-b or Ab-b for 1 hr at 37C.As expected, in wild-type MHC II-expressing cells, en-
docytosed antibodies were targeted via early endo-
somes that labeled for early endosome antigen 1 (EEA1)
to DM-positive MIIC. Mutant Ak-bK225A seemed to be de-
layed in the transfer from EEA1-positive to DM-positive
structures (Figure 6A). To quantify relative uptake of
the two haplotypes, the amounts of fluorescence in se-
lected areas representing either plasma membrane or
intracellular structures were determined in confocal sec-
tions (Figure 6B). The relative efficiencies of uptake were
then calculated as a ratio of the relative fluorescence
intensities at the plasma membrane ((Ak/Ab)PM) with
that at intracellular membranes ((Ak/Ab)IM) (Figure 6C).
Ak-b was endocytosed with a similar efficiency as en-
dogenous Ab-b (ratio 1.1 6 0.24). In contrast, much
less Ak-bK225A was detected intracellularly as compared
to labeled Ab-b (ratio 5.5 6 1.4). This may be explained
either by a reduced rate of uptake or accelerated recy-
cling of Ak-bK225A. The latter explanation is plausible
considering that lack of sorting at MVB of endocytosed
mutant MHC II might well result in accelerated recycling
to the plasma membrane. To distinguish between these
possibilities, antibodies were endocytosed at 20C,
a temperature at which trafficking of endocytosed
MHC II to late endosomes and recycling to the plasma
membrane are severely hampered (Harding and Un-
anue, 1990). Indeed, after 1 hr uptake at 20C, most
endocytosed antibodies reached EEA1-positive early
endosomes rather than DM-positive MIIC (Figure 6A).
Again, wild-type Ak was taken up as efficiently as endog-
enous Ab (ratio 1.3 6 0.25). At this temperature, uptake
of Ak-bK225A was less than 50% efficient compared to
endogenous Ab-b (ratio 2.8 6 0.77; Figures 6B and 6C).
Thus, ubiquitination of MHC II-b is not only required for
sorting at MVB but also for efficient endocytosis. To-
gether, these processes are responsible for intracellular
retention of MHC II in immature DCs.
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889Figure 3. MHC II-b Ubiquitination Requires Ii Processing and Diminishes during DC Maturation
(A) D1 cells were incubated for 3 hr in the absence or presence of MG132, leupeptin, or E64d before lysis. MHC II was immunoprecipitated (IP)
with M5/114, eluted at 20C in SB, and analyzed by immunoblotting for MHC II-b, Ii, or ubiquitin as indicated.
(B) D1 cells were incubated for 0, 2, 4, or 24 hr in the presence of LPS before lysis. Samples of total cell lysates (TL) were immunoblotted for
ubiquitin (left) or MHC II-b (middle bottom). MHC II was immunoprecipitated (IP) with M5/114, eluted at 20C or 100C in SB, and analyzed by
immunoblotting for MHC II-b (right) and ubiquitin (middle top), respectively. The figures are representative for three independent experiments.Discussion
We here demonstrate that in immature DCs a unique and
conserved lysine residue within the cytoplasmic domain
of MHC II-b is oligoubiquitinated after proteolytic
processing of MHC II-associated Ii. Ubiquitination of
mature MHC II is required both for efficient uptake
from the plasma membrane and sorting at MVB into
LV. Together, these two sorting steps result in efficient
intracellular retention of peptide-loaded MHC II, thereby
preventing premature antigen presentation by immature
DCs. In mature DCs, increased expression of MHC
II-peptide complexes at the plasma membrane has
been attributed to several processes: (1) increased tran-
scription of MHC II, (2) increased Ii processing and MHC
II peptide loading (Pierre and Mellman, 1998; Trombetta
et al., 2003), and (3) extended half life of MHC II resulting
from decreased endocytosis rates (McCormick et al.,
2005; Wilson et al., 2004) and recruitment of MHC II
from MIIC toward the plasma membrane (Boes et al.,
2002; Chow et al., 2002; Kleijmeer et al., 2001). We
here demonstrate that the recruitment of peptide-
loaded MHC II to the plasma membrane can be achieved
by blocking MHC II-b ubiquitination.
Endocytosis of mature MHC II occurs via clathrin-me-
diated endocytosis (Dugast et al., 2005; McCormick
et al., 2005; Potolicchio et al., 2005), and a conserved
dileucine-based signal in the COOH terminus of the
cytoplasmic domain of MHC II-b is implicated (Zhong
et al., 1997). Elimination of this signal reduced the
uptake rate but did not block endocytosis of MHC II.This is consistent with a second endocytosis signal for
mature MHC II, which we here identified as an oligoubi-
quitin tag. Conversely, continued but reduced uptake
of MHC II-bK225A in our study may be explained by the
dileucine endocytosis motif. In general it is thought that
monoubiquitination rather than polyubiquitination is
required to downregulate cell-surface receptors by de-
livering these proteins for lysosome-mediated degrada-
tion through the endocytic pathway (Staub and Rotin,
2006). However, it has recently been demonstrated that
recruitment by tandem ubiquitin-interacting motifs in
clathrin adaptors is much more efficient for oligoubiqui-
tinated than for monoubiquitinated membrane proteins
(Barriere et al., 2006; Hawryluk et al., 2006). In addition
to peptide-loaded MHC II, DCs may also express Ii-asso-
ciated MHC II (McCormick et al., 2005; Dugast et al., 2005
and references therein) and empty MHC II (Potolicchio
et al., 2005 and references therein) at their plasma mem-
brane. We here demonstrate that Ii-associated MHC II is
not ubiquitinated, explaining why surface-exposed MHC
II-Ii complexes are endocytosed predominantly through
the interaction of two leucine-based signals encoded on
the cytoplasmic domain of Ii with the clathrin adaptor
AP-2 (McCormick et al., 2005; Dugast et al., 2005 and ref-
erences therein). Surface-exposed empty MHC II lacks
Ii-encoded internalization signals but can be endocy-
tosed via the dileucine motif on MHC II-b. Although we
show that almost all ubiquitinated MHC II was peptide
loaded, we cannot exclude the possibility that also
empty MHC II can be ubiquitinated, thereby facilitating
endocytosis of empty MHC II.
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ularly been implicated in sorting at MVB (Babst, 2005).
Our finding that oligoubiquitination can serve as a sort-
ing signal for MHC II-b at MVB is, however, not unprec-
edented, as illustrated by oligoubiquitination of MHC I
in Kaposi’s sarcoma-associated herpes virus-infected
cells, which results in efficient endocytosis and endoly-
sosomal degradation (Duncan et al., 2006). After uptake
of ubiquitinated cargo, sorting at MVB depends on the
function of a group of conserved proteins that were orig-
inally identified in Saccharomyces cerevisiae (reviewed
in Babst, 2005; Hurley and Emr, 2006; Staub and Rotin,
2006). These include Hrs/Vps27 and the constituents
of three heteromeric protein complexes called ESCRT-
I, II, and III that act sequentially in sorting at MVB.
Consistent with the observation that endogenous
MHC II is ubiquitinated after peptide loading, we ob-
served that also MHC II-bK225A is capable of forming
SDS-stable MHC II-peptide complexes (data not shown).
This is supported by the observation that B cells
expressing MHC II-bK225A were capable of presenting
antigens to T cells (Laufer et al., 1997) and is also in con-
cordance with our observation that ubiquitination of
MHC II is diminished in response to LPS treatment.
Our finding that LPS and other maturation stimuli (data
not shown) rapidly reduce ubiquitination of MHC II
suggests strict regulation of this modification and can
explain the stable expression and increased half-life of
MHC II in maturing DCs. Ubiquitination of MHC II-b in
DCs has not been observed previously, which can be ex-
plained by the relative small amount of ubiquitinated
MHC II-b at steady-state conditions. We favor the idea
that cycles of ubiquitination/deubiquitination may occur
both at the plasma membrane and endosomes, reminis-
cent of membrane proteins whose surface expression is
regulated either by mono- or polyubiquitination, includ-
ing several ion channels, tyrosine kinase receptors, cyto-
kine receptors, and T cell and IgE receptors.
Ideally, we would have liked to study whether forced
ubiquitination of MHC class II in mature DCs would res-
cue its endocytosis and sorting at MVB. However,
forced expression of ubiquitin ligases or ubiquitin chi-
meras may target membrane proteins into the MVB
pathway, irrespective of the physiological relevance.
For example, we considered studying the behavior of
transduced MHC II-b–ubiquitin chimeric complexes. In
our opinion, however, permanent C-terminal monoubi-
quitin-tagged MHC II-b can be expected to behave
Figure 4. Ak-bK225A Is Not Ubiquitinated and Targeted to the Plasma
Membrane
(A) BMDC from either WT or Ab-b-deficient mice were transduced for
either Ak-bWT or Ak-bK225A as indicated. Fixed cells were immu-
nodouble labeled for DM (red) and Ab or Ak (green) as indicated
and analyzed by CSLM. The figures are representative for three
independent experiments.
(B) Nontransduced D1 cells (control) or D1 transduced for either
Ak-bWT or Ak-bK225A were lysed. Endogenous MHC II was immuno-
precipitated (IP) with M5/114 and Ab-a–Ak-b complexes with
10.2.16. Precipitates were eluted as indicated at 100C and immuno-
blotted (Odorizzi et al., 1994) for MHC II-b or ubiquitin. The figure is
representative for two independent experiments.
(C) D1 cells were transduced for either Ak-bWT (left) or Ak-bK225A
(right) and after fixation, immunodouble labeled for Ak (green) and
DM (red) (top) or for Ak (green) and endogenous Ab (red) (bottom).
The figures are representative for four independent experiments.
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891Figure 5. K225 at MHC II-b Is Required for
Sorting of MHC II to LV in Immature DCs
(A) Ultrathin cryosections of either nontrans-
duced (control) or Ak-b or Ak-bK225A-trans-
duced D1 were double immunogold-labeled
for endogenous Ab-b (10 nm gold particles)
and Ak-b (15 nm gold particles; indicated by
arrows). Examples of MVB are shown with
LV and LM indicated. Scale bars represent
200 nm.
(B) Gold particles on the LM versus LV of MVB
were counted, and the ratios (LM/LV) of the
totals from >50 MVB profiles for each condi-
tion are plotted.differently from transient lysine oligoubiquitin-tagged
MHC II-b. First, as indicated above, monoubiquitinated
proteins behave differently compared to oligoubiquiti-
nated proteins with respect to endocytosis and MVB
sorting. Second, deubiquitination of membrane proteins
is crucial for sorting at MVB (Agromayor and Martin-
Serrano, 2006). Fusing a tag to the MHC II tail would
also bypass the elegant switch of sorting motifs that
we disclose in this paper. The endosomal sorting motif
present in the Ii is removed in endosomes but is re-
placed by the ubiquitin tag (in concert with the double
LL motif in the MHC II-b tail) that drives two distinct sort-
ing events, at the plasma membrane and at the MVB LM.
Finally, chimeric ubiquitin tagging of membrane proteins
that normally recycle, such as the transferrin receptor,
results in accelerated MVB sorting and lysosomal deg-
radation irrespective of physiological function (Raiborg
et al., 2002). An alternative approach would be to force
the expression of a ubiquitin ligase. However, as illus-
trated in a recent paper (Ohmura-Hoshino et al., 2006),
MHC II can be downregulated when expressed in 293
cells together with several E3-ligases, c-MIR, or
MARCH-I, highlighting the promiscuous behavior of
these enzymes. Apparently, this system can be pushed
with E3 ligases irrespective of their physiologically rele-
vance. Clearly, to characterize the molecular mecha-
nism regulating ubiquitination of MHC class II requires
more subtle approaches, and the complexity of the
mechanism may resemble that for other receptors,
such as for receptor tyrosine kinases (Urbe, 2005).
Our observation that ubiquitination of MHC II-b
requires prior processing of Ii is consistent with the find-
ing that DCs from cathepsin S-deficient mice showed
aberrant Ii processing and MHC II trafficking (Driessen
et al., 1999; Nakagawa et al., 1999). In this respect, it is in-
teresting to note that nonameric MHC II-ab–Ii complexes
dissociate into dimeric MHC II-ab complexes as a result
of processing of p10 into CLIP. Possibly, association
with Ii prevents premature exposure of MHC II-b to theubiquitination machinery. Our finding that MHC II-b is
ubiquitinated after Ii processing in DCs at physiological
conditions extends on the observations by Ohmura-
Hoshino et al. (2006) and suggests that an endogenous
ligase, possibly a member of the MARCH family, may
associate only after liberation of MHC II-ab dimers in
response to Ii processing. Ubiquitination of MHC II-b is,
however, likely to be regulated by factors other than E3
ligase activity because ubiquitination was strongly re-
duced already after 1–2 hr of LPS treatment, a condition
at which Ii processing was rather accelerated (Figure 3B
and data not shown). In our opinion, the machinery re-
sponsible for regulating MHC class II ubiquitination can
be identified by functional interference only. This com-
plex task is subject to current research.
In conclusion, the described molecular mechanism for
regulating surface expression of MHC II is essential for
DCs to modulate antigen presentation in response to
pathogens. It canbe envisionedthatartificial interference
with MHC II ubiquitination can be a powerful approach
to modulate the immune system for treatment of cancer,
vaccination, or treatment of autoimmune disease.
Experimental Procedures
Reagents
D1, an immature DC line from C57Bl/6 mice, was cultured as de-
scribed (Winzler et al., 1997). BMDCs were isolated as described
(Lutz et al., 1999) from the bone marrow of WT C57BL/6 mice or
B6.129-H2-Ab1tm1Gru N12 (Taconic, Denmark), an Ab-b-deficient
C57BL/6 mouse (Grusby et al., 1991).
LPS (Escherichia coli, serotype 026:B6) was used at 10 mg/ml,
Leupeptin at 100 mg/ml, MG132 at 20 mM, and E64d at 100 mM (all
from Sigma). Rabbit polyclonal antibodies directed against the
cytoplasmic domains of DM (Barois et al., 1998), MHC II-b, and Ii
(Barois et al., 1997) were from N. Barois (University of Oslo, Oslo,
Norway). Anti-mouse MHC II M5/114 (Bhattacharya et al., 1981)
and Y3P (Janeway et al., 1984) were both provided by S. Amigorena,
and 15G4, directed against Ab/CLIP (Nakagawa et al., 1999), was
a gift of A. Rudensky. HRP-conjugated and agarose bead-conju-
gated anti-ubiquitin P4D1 were from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Rat anti-mouse isotype control was
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D1 cells were transduced for either Ak-bWT or Ak-bK225A.purchased from Serotec (Raleigh, SC), and anti-tubulin 1A2 was
from Sigma.
Protein Isolation and Analyses
For immunoprecipitations, DCs were lysed at 4C in 1% Triton X100,
1 mM EDTA, 150 mM NaCl, 20 mM Tris/HCl (pH 8), 10 mM N-ethyl-
maleimide (Sigma), and complete protease inhibitor mix (Roche
Molecular Biochemicals, Almere, The Netherlands), and nuclei
were removed by centrifugation. Immunoprecipitations were per-
formed as indicated in the figure legends. Protein G-agarose beads
(Sigma Aldrich, Zwijndrecht, The Netherands) were precoupled to
either Y3P, M5/114, 15G4, or IgG2b rat anti-mouse isotype control
antibodies in lysis buffer, added to the cell lysates, and gently mixed
for 1 hr at 4C. The beads were then washed, and immunoprecipi-
tated MHC II was eluted either in SDS sample buffer (2% SDS,
62.5 mM Tris-HCl [pH 6.8], 10% Glycerol) for 30 min or 16 hr at
room temperature or 5 min at 100C. When indicated, MHC II was
eluted in 1% SDS at 100C for subsequent immunoprecipitation of
ubiquitinated proteins. For this goal, the eluate was diluted 10 times
in lysis buffer and precleared for nonspecific binding with nonrele-
vant IgG2-conjugated agarose beads. Supernatants were collected
and incubated with anti-ubiquitin P4D1 conjugated agarose beads
or control antibody-conjugated beads, both from Santa Cruz Bio-
technology for 1 hr at 4C. Nonspecifically associated proteins
were removed by washing in 4 M Urea, after which ubiquitinated pro-
teins were eluted off the beads by boiling in SDS sample buffer.
Western blotting was performed according to standard techniques.
For mass spectrometric analyses, protein bands were subjected to
in-gel tryptic digestion and subsequent LC-MS/MS analysis as de-
scribed previously (van Balkom et al., 2005). The data files obtained
from LC-MS/MS experiments were converted into peaklist files (*.pkl
files) with ProteinLynx Browser version 2.1 software (Micromass)
and subsequently submitted to the Mascot search software (Matrix
Science, London, UK) (Perkins et al., 1999). The allowed peptide
mass tolerance was 0.4 Da, fragment mass tolerance of 0.2 Da,
allowing 2 missed cleavages, to search the mouse IPI database
version 3.11. (Kersey et al., 2004).
Constructs and Retroviral Transduction of DCs
Ak-bWT and Ak-bK225A cDNA in pRc/CMV vector were kindly provided
by T. Laufer (Harvard School of Public Health, Boston, MA) (Laufer
et al., 1997). cDNAs were amplified by PCR and cloned into pQIXN
(Clontech, Mountain View, USA), and sequences were verified.
Retroviral particles were produced by 293T Phoenix-Eco cells after
cotransfection with the pQ vectors and pCl-Eco (provided by H.
Rozemuller, Utrecht Medical Centre, Utrecht). Harvested viruses
were filtered, mixed with polybrene (4 mg/ml, Sigma), and used to
infect either D1 or BMDC by spin occulation 7 days after isolation.
Transduced BMDC were analyzed after 2 days of expression by
immunofluorescence or FACS, and transduced D1 were maintained
as stable cell cultures.
Microscopy
Cells grown on glass coverslips were fixed and immunolabeled for
DM (2E5A, BD Biosciences, San Jose, CA), for Ab-a (Y3P), for Ak-b
(A) Cells were allowed to bind and endocytose PE-conjugated 10-3.6
for transduced Ak-b (green) at indicated temperatures, fixed, and
costained for the early endosomal marker EEA1 (red) and DM
(blue). The figure is representative for three independent experi-
ments.
(B) Cells were allowed to bind and endocytose PE-conjugated 10.3-6
for transduced Ak-b (green) and APC-conjugated M5-114 (red) for en-
dogenous Ab-b for 1 hr at 37C or 20C as indicated. Cells were
washed and fixed, and images were acquired by CSLM. Areas repre-
sentative for plasma membrane (asterisk) or intracellular structures
(dot) were encircled (see indicated examples), and the integrated
densities of fluorescence within these areas was determined for 10
distinct samples for each condition.
(C) The relative efficiencies of uptake were then determined by
comparing the ratio of fluorescence at the plasma membrane (PE/
APC) with that at the internal membranes (SD are indicated in the
bar diagrams and are given in the text).
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893(PE-10.3-6, BD Biosciences or 10.2.16, kind gift of S. Ostrand-
Rosenberg). Nonlabeled antibodies were visualized with donkey
anti-mouse Alexa 568 or goat anti-rat Alexa 488 (Molecular Probes,
Eugene, OR). Confocal microscopy was performed on a Bio-Rad
Radiance 2100MP confocal and multiphoton system (Zeiss/Bio-
Rad, Hertfordshire, UK).
For internalization studies, labeled antibodies (PE 10.3-6 and APC
M5-114, both from BD Biosciences) were incubated with transduced
D1 for 1 hr at indicated temperatures. Cells were washed and fixed,
and images were acquired by confocal microscopy. Relative pres-
ence of both antibodies was measured as integrated densities (ID)
from regions of interest drawn either inside cells or on the plasma
membrane of confocal sections. Ratios (plasma membrane divided
by the internal pool ID) of these values were determined for each
marker in 10 cell profiles for each condition with Image J software.
For immunoelectron microscopy, cells were fixed, and single- or
double-immunogold labelings of ultrathin cryosections were per-
formed as described (Raposo et al., 1997). Sections were observed
under a Philips CM120 Electron Microscope (FEI Company, Eindo-
ven, The Netherlands) equipped with a digital camera Keen View
(SIS, Germany). Ab-b was labeled with M5/114, followed by rabbit
anti-rat Ig (Dako, Denmark) and protein A conjugated to 10 nm
gold particles. Ak-b was labeled with mouse monoclonal 10.3-6
followed by protein A conjugated to 15 nm gold particles. Protein
A conjugated to gold particles were purchased from Cell Micros-
copy Centre (AZU Utrecht, the Netherlands). Label for MHC II was
considered to be associated with the LM when the gold particle
was within 20 nm of the LM and with no cross-sectioned LM in the
direct vicinity.
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